[Treatment of senile degenerative maculopathies by etaretin. Prospects of success and economical points of view (author's transl)].
D000367:Age Factors; D000368:Aged; D000818:Animals; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000627:therapeutic use; D012160:Retina; D012162:Retinal Degeneration / Q000188:drug therapy*; D013552:Swine; D013997:Time Factors; D014020:Tissue Extracts / Q000627:therapeutic use*; D014792:Visual Acuity; D014801:Vitamin A / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D010743:Phospholipids; D014020:Tissue Extracts; D014801:Vitamin A; D014810:Vitamin E
Die Behandlung seniler degenerativer Makulopathien mit Etaretin--Erfolgsaussichten und wirtschaftliche Gesichtspunkte